Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
116 studies found for:    MYL2
Show Display Options
Rank Status Study
1 Completed Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
Conditions: Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Promyelocytic Leukemia (M3);   Childhood Acute Promyelocytic Leukemia (M3);   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: tretinoin;   Drug: daunorubicin hydrochloride;   Drug: cytarabine;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: arsenic trioxide
2 Recruiting Acute Promyelocytic Leukemia 2006 (APL)
Condition: Leukemia, Promyelocytic, Acute
Interventions: Procedure: Arsenic trioxide;   Procedure: ATRA
3 Completed A Randomized Trial Assessing the Roles of AraC in Newly Diagnosed APL Promyelocytic Leukemia (APL)
Condition: Leukemia, Promyelocytic, Acute
Intervention: Drug: Arac
4 Recruiting Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)
Condition: Leukemia
Intervention: Drug: Ara-c
5 Completed Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia
Condition: Leukemia
Intervention: Drug: arsenic trioxide
6 Active, not recruiting Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
Conditions: Childhood Acute Promyelocytic Leukemia (M3);   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Interventions: Drug: arsenic trioxide;   Drug: mitoxantrone hydrochloride;   Other: diagnostic laboratory biomarker analysis;   Drug: idarubicin;   Drug: tretinoin;   Drug: cytarabine;   Drug: mercaptopurine tablet;   Drug: methotrexate
7 Completed Safety, Efficacy, & Pharmacokinetic Study of Tamibarotene to Treat Patients With Relapsed or Refractory APL
Condition: Acute Promyelocytic Leukemia
Intervention: Drug: Tamibarotene
8 Completed High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With T(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With T(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With T(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Acute Promyelocytic Leukemia (M3);   Adult Erythroleukemia (M6a);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Adult Pure Erythroid Leukemia (M6b);   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Burkitt Lymphoma;   Childhood Acute Erythroleukemia (M6);   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloblastic Leukemia With Maturation (M2);   Childhood Acute Myeloblastic Leukemia Without Maturation (M1);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Acute Myelomonocytic Leukemia (M4);   Childhood Acute Promyelocytic Leukemia (M3);   Childhood Chronic Myelogenous Leukemia;   Childhood Myelodysplastic Syndromes;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   De Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Peripheral T-Cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult Non-Hodgkin Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Myelodysplastic Syndromes;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenstrom Macroglobulinemia
Interventions: Drug: busulfan;   Drug: cyclophosphamide;   Procedure: allogeneic bone marrow transplantation;   Drug: methylprednisolone;   Drug: methotrexate;   Drug: cyclosporine
9 Withdrawn New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic Leukemia
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: NRX 195183 (retinoid analogue);   Drug: Arsenic Trioxide
10 Completed Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission
Condition: Leukemia, Myelocytic, Acute
Interventions: Drug: gemtuzumab ozogamicin;   Drug: ATRA plus 6-MP and MTX
11 Active, not recruiting Phase III Trial in Acute Promyelocytic Leukemia Patients
Condition: Leukemia
Interventions: Drug: arsenic trioxide;   Drug: idarubicin;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: all-trans retinoic acid;   Drug: all-trans retinoic acid (ATRA)
12 Active, not recruiting All-trans Retinoic Acid, and Arsenic +/- Gemtuzumab
Condition: Acute Promyelocytic Leukemia
Interventions: Drug: All-Trans Retinoic Acid (ATRA);   Drug: Arsenic Trioxide (ATO);   Drug: Idarubicin
13 Recruiting A Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia
Condition: Childhood Acute Promyelocytic Leukemia
Interventions: Drug: ATO;   Drug: RIF;   Drug: ATRA;   Drug: mitoxantrone;   Drug: Ara-C;   Drug: MTX;   Drug: 6MP;   Other: intrathecal injection
14 Completed Combination Chemotherapy in Treating Patients With Acute Promyelocytic Leukemia
Condition: Leukemia
Interventions: Drug: arsenic trioxide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: tretinoin
15 Recruiting Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
Conditions: Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Precancerous Condition;   Secondary Myelofibrosis
Interventions: Drug: Busulfan;   Drug: Cytarabine;   Drug: Fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
16 Completed Chemotherapy in Treating Children With Recurrent Acute Myeloid Leukemia
Condition: Leukemia
Interventions: Biological: filgrastim;   Drug: cladribine;   Drug: idarubicin
17 Completed
Has Results
Vorinostat in Treating Patients With Acute Myeloid Leukemia
Conditions: Adult Acute Erythroid Leukemia (M6);   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloblastic Leukemia With Maturation (M2);   Adult Acute Myeloblastic Leukemia Without Maturation (M1);   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Myelomonocytic Leukemia (M4);   Adult Acute Promyelocytic Leukemia (M3);   Recurrent Adult Acute Myeloid Leukemia;   Refractory Cytopenia With Multilineage Dysplasia;   Secondary Acute Myeloid Leukemia;   Untreated Adult Acute Myeloid Leukemia
Intervention: Drug: vorinostat
18 Recruiting Acute Promyelocytic Leukemia (APL) Treated With ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin
Condition: Leukemia
Interventions: Drug: ATRA;   Drug: ATO;   Drug: GO (Gemtuzumab ozogamicin);   Drug: Methylprednisolone
19 Recruiting Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant
Conditions: Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Acute Promyelocytic Leukemia (M3);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma;   Anaplastic Large Cell Lymphoma;   B-cell Adult Acute Lymphoblastic Leukemia;   Chronic Eosinophilic Leukemia;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cytomegalovirus Infection;   de Novo Myelodysplastic Syndromes;   Essential Thrombocythemia;   Extramedullary Plasmacytoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Isolated Plasmacytoma of Bone;   Monoclonal Gammopathy of Undetermined Significance;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Peripheral T-cell Lymphoma;   Polycythemia Vera;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Primary Central Nervous System Hodgkin Lymphoma;   Primary Central Nervous System Non-Hodgkin Lymphoma;   Primary Myelofibrosis;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Adult T-cell Leukemia/Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Multiple Myeloma;   Stage I Small Lymphocytic Lymphoma;   Stage IA Mycosis Fungoides/Sezary Syndrome;   Stage IB Mycosis Fungoides/Sezary Syndrome;   Stage II Adult Hodgkin Lymphoma;   Stage II Adult T-cell Leukemia/Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage IIA Mycosis Fungoides/Sezary Syndrome;   Stage IIB Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Adult T-cell Leukemia/Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Multiple Myeloma;   Stage III Small Lymphocytic Lymphoma;   Stage IIIA Mycosis Fungoides/Sezary Syndrome;   Stage IIIB Mycosis Fungoides/Sezary Syndrome;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Adult T-cell Leukemia/Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Stage IVA Mycosis Fungoides/Sezary Syndrome;   Stage IVB Mycosis Fungoides/Sezary Syndrome;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
Interventions: Biological: tetanus-CMV fusion peptide vaccine;   Other: laboratory biomarker analysis
20 Recruiting Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 2 Diabetes Mellitus Patients (INSTRIDE 2)
Condition: Type 2 Diabetes
Interventions: Drug: Mylan's insulin glargine;   Drug: Lantus®

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years